However, findings from the present investigation seem contrary to that notion, and run against the prevailing view that the greater availability of BDNF among homozygous Val carriers may provide (although inconsistently noted) neuroprotection against depressive symptoms (Verhagen et al., 2010), as Study 1 did not reveal group differences on depression scores as a function of BDNF genotype. The gene discussed is BDNF; the disease is depressive symptom measurement.